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Abstract
Background: In about 40% of the couples, the cause of infertility problems is attributed
to men because of low sperm production and disturbed motility of sperm. Pieces
of evidence show that Myo-inositol has a potential role for the treatment of sperm
morphology and male fertility.
Objective: This study aimed to determine the effect of Myo-inositol on the sperm
parameters and fertility rate in patients with oligoasthenospermia treated by intrauter-
ine insemination (IUI).
Materials and Methods: This study was a randomized clinical trial conducted on 37
patients with oligoasthenospermia treated by IUI during 2016-2017. In this study, the
patients were randomly divided into two groups of oligoasthenospermia treated with
(Case group) and without Myo-inositol (Control group). The case group received 0.5 ml
of Myo-inositol with a concentration of 2 mg/ml and incubated at 37°C incubator for 2
hr, but the control group had no interventions.
Results: The results of this study showed that although there was no significant
difference in sperm parameters including sperm motility and concentration before
processing with Myo-inositol in the case group, but there was a significant increase
in sperm motility during the treatment with Myo-inositol. The therapeutic effect of this
method was confirmed on induction of pregnancy in 18% of the treated patients, in
such a way that was about twice greater than those who did not receive the drug.
Conclusion: According to the results of this study, the use of Myo-inositol is efficient
enough to change sperm parameters to increase the chance of fertility.
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1. Introduction
Myo-inositol is a sugar-like molecule considered
as a member of the vitamin B complex. It is one
of the most important cell membrane elements
involved in the synthesis of lipids and cell growth
and is also considered as one of the countless
neurotransmitter precursors such as serotonin.
Recently, various studies have shown that Myo-
inositol is one of the precursors for the synthesis
of phosphatidylinositol polyphosphates (1).
Myo-inositol plays a significant role in various
processes associated with reproduction including
gametes development, oocyte maturation,
reproduction, and fetal development (2). Recent
evidences indicate that Myo-inositol has a phys-
iologic and therapeutic role in the improvement
of human reproductive performance (3-5). Myo-
inositol is also used to treat polycystic ovary
syndrome (PCOS) and is taken into consideration
as a method for induction of reproductive capacity.
This substance is able to induce ovulation in
ovaries and fertilization in patients with PCOS (6).
Considering the role of Myo-inositol in male
fertility, it has been shown that Myo-inositol con-
centration in seminiferous tubules is higher from
the serum (6). Thus, Myo-inositol concentration
will increase by the movement of spermatozoa
through epididymis and vas deferens (7).
The term ”oligoasthenospermia” refers to the
reduced number or movement ability of sperms
and is a disorder that has been frequently reported
in recent years. Accordingly, a change in sperm
morphology can affect male fertility because
of the production of Reactive Oxygen Species
(ROS) affecting the motility and the morphology of
sperms. Spermatozoa is covered by amorphous
fibrosis in patients with oligoasthenospermia.
It has also been shown that the treatment with
Myo-inositol reduces the presence of amorphous
fibrosis (8). On the other hand, Myo-inositol is able
to regulate the osmotic property of the seminal
fluid, while low osmolarity of this substance
decreases the motility and the viscosity of sperm
(9).
An increase in the amount of inositol monophos-
phates 1, an enzyme in dephosphorylating of
phosphatidylinositol, is observed in patients with
asthenozoospermia leading to the low motility of
sperm (10, 11).
Evidence shows the potential role of treatment
with Myo-inositol for improving the morphology
of sperm and male fertility. Therefore, this study
aimed to determine the effect of Myo-inositol on
the sperm motility and the treatment of male infer-
tility in order to indicate the role of this substance
as a therapeutic method in male infertility.
2. Materials and Methods
This study was a double-blind randomized
clinical trial conducted on 37 men with
oligoasthenospermia treated with intrauterine
insemination (IUI) during 2016-2017.
Our inclusion criteria were the couples with
male factor infertility (oligoasthenospermia or
asthenospermia) during the last 12 months, despite
the normal female factors, hysterosalpingography,
and hormonal tests. The exclusion criteria were
severe oligo-astheno-teratospermia (OAT) or other
male factors, untreated hormonal problems, BMI >
35, genital abnormalities, and partner women aged
over 38 yr. The participants were initially evaluated
through sperm analysis. In this regard, the term
”oligospermia” refers to the sperm density of 5-20
million per milliliter, and ”asthenospermia” refers
to the sperm motility of < 40% with progressive
motility (12).
In the present study, 73 participants were
enrolled initially, out of which 13 men were later
excluded for falling under the exclusion criteria
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such as immigration to other cities and treat-
ment discontinuation, not referring at the sched-
uled time, and not providing the results of their
pregnancy test. Finally, 60 men remained to
be randomly divided into the two groups (Fig-
ure 1).
Figure 1. CONSORT diagram of the trial.
2.1. Preparation and analysis of sample
semen
The semen sample for IUI treatment was
collected through masturbation 48-72 hr after the
last ejaculation and kept in a sterile container
and placed at 37°C incubator for 30 min. Upon
the liquefaction of the samples, sperm analysis
was performed based on the version 2010 WHO
criteria, and sperms were isolated from the plasma
through the gradient method (sill-select plus
commercial kit).
2.2. Sperm wash through gradient
method
At first, 1.5 ml of gradient medium with a
concentration of 80% was poured into a falcon
tube, and 1.5 ml of 40% gradient solution was
slowly added into it, so that the 40% medium
was completely at the top. Then, 2 ml of seminal
fluid was slowly added to becentrifuged for 15
min at 3000 rpm. The sediment formed at the
bottom of the tube was taken with a pipette
and poured into another tube, and then 1.5 cm
of sperm wash medium was added. It was also
centrifuged at 3000 rpm for 5 min. After that,
the top medium was taken with a pipette and 1.5
ml sperm wash medium was added again and
centrifuged at 3000 rpm for 5 min. In the next
stage, the upper medium was removed and the
remaining sperms at the bottom of the tube were
mixed with 1 ml of the medium and prepared for
IUI.
2.3. Intervention method
After the sperm separation, the participants were
randomly divided into the two groups: the cases
and the controls (n= 30/each) using a random
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number table. The control group had no interven-
tion and the sperms were incubated for 2 hr at 37°C
in 0.5 mL of the flushing medium in the special
kit. In the case group, 0.5 ml of Myo-inositol at a
concentration of 2 mg/ml was added to each men
sperms, and they were incubated for 2 hr at 37°C
incubator (the drug was licensed by the Ministry
of Health with the IRC code of 7897458758743114
and the drug code of 104507 from Merck Com-
pany in Germany). After the incubation, the sperm
parameters were re-examined and registered as
triple blind. The studied parameters included the
number of live sperms (viability), sperm motility,
morphology, agglutination, volume, acidity, dura-
tion of liquefaction, DNA fragmentation index (DFI),
and fertility.
2.4. The sperm chromatin dispersion
(SCD) test sperm chromatin dis-
persion test
To examine DNA fragmentation index (DFI) in
both the groups, the SDFA kit (Sperm DNA Frag-
mentation Assay [Halosperm]) was used. In this
test, sperm DNA and chromatin were denatured
in a micro gel context affected by an acid treat-
ment. In the next step, chromatin proteins were
removed and DNA strands were spread around the
sperm’s head as far as possible, and they were
visible as a halo around the sperm’s head through
coloration. Meanwhile, sperm DNA fragmentation
led to the lack of the spread of DNA strands
without observation of the halo, or with observation
of very small haloes around the sperm’s head.
The normal range of this measurement is such
a way that specimens with SDFA < 15% had a
good rating and their DNA fragmentation rate was
very low. But the SDFA from 15% to 30% had a
low fragmentation rate (average rating) and SDFA
> 30% had a high fragmentation rate (abnormal
rating).
2.5. Intrauterine insemination
The prepared specimens were inseminated into
the uterus using a special IUI catheter. In this
method, the sperms were washed in a sterile
medium, and dead sperms and other cells were
separated. The sperms prepared for insemination
were passed through the cervix and injected
directly into the uterus by a gynecologist using
a catheter. This would shorten the pathway for
the sperm to reach the ovum inside the uterine
tube andwould increase the probability of reaching
the ovum. In addition, dead sperms and other
cells as well as various materials that come with
healthy sperms were separated, and thus, the
active sperms were entered a nutritious environ-
ment that could easily move. Fifteen days later,
serum B-HCG levels were checked for clinical
pregnancy.
2.6. Ethical consideration
This study was approved by the local
ethics committee of Iran University of Medical
Sciences (IR.IUMS.FMD.REC1396.9211290014) and
registered in the Iranian Registry of Clinical Trials
(IRCT20181031041519N1). In this study, informed
consent was obtained from all participats in the
study and their partners.
2.7. Statistical analysis
The results were presented as mean and
standard deviation (mean ± SD) for quantitative
variables and as percentages for qualitative
variables. Independent t-test and Chi-square test
were used to compare quantitative and qualitative
variables, respectively. Paired t-test and repeated
measurement ANOVA was also used to determine
the changes in the indices before and after the
intervention. P < 0.05 was considered significant.
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3. Results
In the present study, 37 couples with male
infertility (oligoasthenospermia), were enrolled into
the two groups of with and without Myo-inositol
treatment. Our results showed that the mean age
of the women in the case and control groups were
29.92 ± 5.75 yr and 30.88 ± 3.54 yr, respectively,
which was not significantly different. Also, the
mean Body Mass Index (BMI) and infertility of the
women were 23.92 ± 4.15 and 3.46 ± 2.71 in the
case group and 22.92 ± 2.75 and 2.85 ± 2.64
in the control group, respectively (p = 0.362, p =
0.240) (Table I). In this study, the mean FSH, TSH,
AMH, PRL, and follicles count of the women in
the two groups were compared, and the results
showed that these differences were not statistically
significant in the two groups (Table I). On the other
hand, Myo-inositol did not have any effect on the
DFI increase and DNA damage (Figure 2). In this
study, the mean sperm volumes in the case and
control groups were 2.75 ± 1.07 ml and 2.58 ±
1.19 ml, respectively, without significant difference
(p = 0.671). Also, the mean sperm liquefaction times
in the control and case groups were 15.08 ± 3.54
min and 17.38 ± 9.87 min, respectively (p = 0.425).
The acidity of sperm in the two groups showed no
significant difference (p = 0.180) (Table II). The sizes
of agglutination in both the case and control groups
were also measured after the case. The results
are shown in Table III without significant difference
between the sizes of sperm agglutination in the
two groups (p = 0.362). The treatment by Myo-
inositol had a positive effect on 18% of the patients
and increased the chance of fertility. This rate
was lower in the control group (about 9%), which
was statistically significant (p = 0.023) (Table III;
Figure 3). The sperm concentration after sperm
processing had no significant difference between
the two groups before, after, and 2 hr after the
initial preparation stages, and the treatment was
not effective on the sperm concentration or sperm
count (Figure 4; Table IV). Sperm motility was also
examined and the results showed that there was a
significant difference between the two groups, that
is, the treatment increased sperm motility before,
after, and 2 hr after the initial preparation stages
(Figure 5; Table IV).
Table I. Comparison of the baseline variables in the case and control groups
Variables Case group (n = 13) Control group (n = 24) P-value* (95% CI)
Age of women 29.92 ± 5.75 30.88 ± 3.54 0.625 (-2.14, 4.04)
Age of men 36.08 ± 5.88 33.96 ± 4.68 0.624 (-5.70, 1.46)
BMI 23.92 ± 4.15 22.92 ± 2.75 0.240 (-3.30, 1.30)
Infertility duration 3.46 ± 2.71 2.85 ± 2.64 0.363 (-2.47, 1.25)
Follicle 3.07 ± 1.65 3.04 ± 2.13 0.959 (-1.42, 1.35)
FSH 6.80 ± 4.27 6.03 ± 2.27 0.694 (-4.91, 3.37)
AMH 6.21 ± 4.48 3.50 ± 3.09 0.272 (-7.92, 2.48)
PRL 11.57 ± 6.51 18.52 ± 7.65 0.243 (-6.90, 18.18)
TSH 1.59 ± 0.45 1.58 ± 0.34 0.954 (-0.43, 0.40)
Data presented as mean ± SD; *Independent t-test
BMI: Body mass index; FSH: Follicle stimulating hormone; AMH: Anti mullerian hormone; PRL: Prolactin; TSH: Thyroid-stimulating
hormone
Table II. Evaluation of sperm volume, PH, and liquefaction duration in the case and control groups
Variables Case group (n = 13) Control group (n = 24) P-value* (95% CI)
Vulome 2.75 ± 1.07 2.58 ± 1.19 0.671 (-0.97, 0.63)
Liquefaction duration 15.08 ± 3.54 17.38 ± 9.87 0.425 (-3.48, 8.08)
PH 7.09 ± 0.09 7.038 ± 0.11 0.180 (-0.13, 0.02)
Data presented as mean ± SD; *Independent t-test
PH: PH scale
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Table III. Comparison of sperm agglutination in the case and control groups
Variables Case group (n = 13) Control group (n = 24) P-value*
Agglotination
Most 1 (7.7) 1 (4.2)
Few 5 (38.5) 6 (25)
Somewhat 2 (15.4) 1 (4.2)
None 5 (38.5) 16 (66.7)
0.362
Results
Positive 2 (15.4) 2 (8.3)
Negative 11 (84.6) 22 (91.7)
0.023
Data presented as frequecy (%); *Chi-square test
Table IV. Comparison of sperm parameters in the case and control groups
Variables Case group (n = 13) Control group (n = 24) P-value
Motility
Before 35.62 ± 9.73 24.71 ± 12.13
After 79.85 ± 11.66 57.54 ± 25.74
After 2 hr 87.23 ± 11.93 56.96 ± 26.67
0.0001
Sperm count (milion)
Before 14.76 ± 2.29 18.20 ± 1.80
After 9.84 ± 1.34 14.41 ± 1.51
After 2 hr 9.84 ± 1.34 14.12 ± 1.39
0.453
Morphology (%)
Before 0.77 ± 0.21 0.33 ± 0.09
After 2.90 ± 0.42 1.77 ± 0.33
After 2 hr 2.90 ± 0.42 1.77 ± 0.33
0.974
Figure 2. Sperm DFI examination in both the case and control groups (ANOVA test, F = 0.152, p = 0.014).
Figure 3. Pregnancy rate in the two groups (Independent t-test, df = 2, p = 0.050).
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Figure 4. Comparison of the mean number of viability before
and after treatment in the case and control groups.
Figure 5. Comparison of the mean sperm motility (Figure A:
Total mobility; Figure B: Progressive mobility) before, after, and
2 hr after the initial preparation stages in the case and control
groups.
4. Discussion
The present study showed that the use of
Myo-inositol was effective enough to change the
properties of the sperm, leading to a high chance
of fertility. Although, there was no significant differ-
ence in the sperm properties such as spermmotility
before treating the sperm with inositol in the
intervention group, there was a significant increase
in the sperm motility after the treatment by Myo-
inositol. Also, there was a significant improvement
in the progressive sperm motility after treatment
byMyo-inositol. This therapeutic method increased
the fertility rate in the patients whose sperms were
incubated with Myo-inositol by up to 18%, which
was about twice greater than those who did not
receive the drug. In the last few years, many scien-
tific studies have been done and showed that Myo-
inositol was one of the precursors for the synthesis
of phosphatidylinositol (1). A growing number of
studies about Myo-inositol support the theory of
its physiological and therapeutic role in improving
human fertility (3, 4). This finding has been widely
studied in the field of increasing fertility through
medical science and has been reported as a major
regulator in a wide range of cellular processes
such as gamete growth, oocyte maturation, fertility,
and prenatal development (2). Myo-inositol has
been specifically studied for the treatment of PCOS
as a new method for ovulation induction. Myo-
inositol restores spontaneous ovarian activity and
increases the chances of fertility in patients with
PCOS (9). Sperm dysfunction is one of the main
causes of infertility, and its initial manifestation
is low motility of sperms (13-15). Regarding the
role of Myo-inositol in male fertility, Chauvin et al.
showed that Myo-inositol concentration in seminal
tubes was higher from the serum (16). In addition,
it was reported that Myo-inositol increases the
transmission of sperms through epididymis (7).
The sperms of patients with Oligoasthenosper-
mia are completely covered with ”fibers without
amorphous materials” which reduces the cellular
mobility. Clone et al. showed that the treatment
with Myo-inositol could reduce the presence of
these materials (8). It has also been observed
that Myo-inositol plays an important role in the
regulation of seminal fluid osmolarity since hypo-
and hyper-osmotic conditions significantly reduce
the motility and progressive speed of sperms (9).
Myo-inositol increases the amount of inositol-1
Monophosphatase involving in the dephosphory-
lating of phosphatidyl inositol and plays a key role
in the patients with Oligoasthenospermia (10). In
fact, the change in the expression of IMPA-1 in
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the patients with Oligoasthenospermia can alter
the signaling of phosphatidyl enzyme and leads
to the low motility of sperm (10). Gulino et al.
conducted another study in Italy and showed
that the administration of Myo-inositol improved
seminal fluid parameters in both the control and
the oligoasthenospermia groups and was a useful
treatment in increasing the probability of fertility in
couples.
5. Conclusion
The present study showed a significant increase
in their motility after treatment by Myo-inositol
showing the efficacy of changes in the sperm
properties induced by Myo-inositol leading to the
high chance of fertility in couples. Furthermore,
there was a significant improvement in the
progressive sperm motility after treatment by
Myo-inositol. The therapeutic effect of this method
increased the fertility rate in patients whose
sperms were incubated with Myo-inositol by up
to 18%, which was about twice greater than those
who did not receive Myo-inositol.
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